热门资讯> 正文
Vigil Neuroscience在主导资产的中期研究中失败
2025-06-04 19:26
- Vigil Neuroscience (NASDAQ:VIGL) announced on Wednesday that a mid-stage trial for its lead candidate, iluzanebart, didn’t succeed in patients with a rare neurological disease called adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
- The Watertown, Massachusetts-based biotech, which recently agreed to be acquired by Sanofi (SNY), said that based on the results, the company has decided to discontinue a Phase 2 long-term extension study for iluzanebart, also known as VGL101.
- While the experimental therapy failed to achieve beneficial effects on biomarker or clinical efficacy endpoints in the open-label trial named IGNITE, Vigil (NASDAQ:VIGL) said that the drug at 20 mg/kg and 40 mg/kg doses indicated a favorable safety, tolerability, and pharmacokinetic profile.
- Sanofi’s (GCVRZ) $470M deal in May to acquire Vigil (NASDAQ:VIGL) didn’t include iluzanebart.
More on Vigil Neuroscience
- Key deals this week: Foxconn, Sanofi, Honeywell, Adriatic Metals, Informatica and more
- Sanofi to buy Vigil Neuroscience in $470M deal (update)
- Seeking Alpha’s Quant Rating on Vigil Neuroscience
- Historical earnings data for Vigil Neuroscience
- Financial information for Vigil Neuroscience
推荐文章
华盛早报丨美国退休金突发！401K可投资加密货币；火箭制造商FLY上市首日暴涨34%
美股机会日报丨重大利好！特朗普将允许养老金投资加密货币；多邻国绩后狂飙26%
一图看懂 | 中芯国际Q2营收22.09亿美元，同比增长16.2%，股东应占利润同比减少19.5%
非农大修预示美国经济拐点？又一联储官员拉响警报 降息呼声渐高
新股申购 | “减肥药概念” 银诺医药-B一手入场费3773.68港元，引入迈富时等基石投资者
惊现“乌龙指”？美债昨夜盘中闪崩引各方猜测 最诡异的是……
外盘头条：特朗普对印度额外征收25%关税，非农修正或预示美国经济转折
苹果宣布再投1000亿美元支持美国制造 股价创近三个月来最大单日涨幅
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
